Hepatocellular carcinoma is a highly heterogeneous disease both at the molecular and clinical levels. Intratumor morphologic and genetic heterogeneity adds a new level of complexity in our understanding of liver carcinogenesis, and it is likely an important determinant of primary and secondary resistance to targeted therapies. Clin Cancer Res; 21(8); 1786-8.
No takes yet. Share an insight, caveat, or question.
Nault et al. (2015) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: